Search Results 331-340 of 923 for ai官网旗舰店,ai创作网,网络智能ai,ai工具合集官网,ai生成效果图网站,等欢迎访问豌豆Ai站群搜索引擎系统官方网站:www.wd.chat

1. A Study to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors - Mayo Clinic

   About this study. To evaluate the effectiveness of NY-ESO-1-Specific (c259) T Cells, alone or in combination with other anti-cancer agents, in HLA-A*02:01, ...

2. Collaborators - T Cell Engineering Laboratory - Mayo Clinic Research

   Faculty and staff in the T Cell Engineering Lab led by Saad J. Kenderian, M.B., Ch.B., at Mayo Clinic are collaborating with multiple programs and ...

3. Xiaoying Liang, Ph.D. - Doctors and Medical Staff - Mayo Clinic

   2010. Residency - CAMPEP Medical PhysicsDepartment of Radiation Oncology, Virginia Commonwealth University · 2001. PhD - Nuclear PhysicsUniversity of Paisley.

4. Phase III Copanlisib in Rituximab-refractory iNHL - Mayo Clinic

   Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

5. A Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics (PK/PD) in Patients With Hematologic Malignancies - Mayo Clinic

   The purpose of this study is to evaluate the safety and tolerability of APG-2575 as well as dose escalation and dose expansion stages. Participation eligibility.

6. Perceived Financial Hardship in Patients with Multiple Myeloma and Their Caregivers - Mayo Clinic

   About this study. The purpose of the study is to examine the agrrement in perception of finacial hardship (FH) and the perceived stress in patients with ...

7. Past Lab Members - Mayo Clinic Research

   View past members of Mayo Clinic's Bone Injury and Repair Lab led by Abhishek Chandra, Ph.D., M.S..

8. Collaborators - Molecular Analysis of Human Diseases Laboratory - Mayo Clinic Research

   Collaborators. Dr. Hawse is involved in ongoing research collaborations at Mayo Clinic and other institutions. Mayo Clinic collaborators. Breast cancer.

9. ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection - Mayo Clinic

   About this study. Subjects will receive an oral dose of SER-109 in 4 capsules once daily for 3 consecutive days in Treatment Group I or matching placebo ...

10. Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation - Mayo Clinic

    Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With ...